Clinical Trials

UCLA Radiological Sciences is engaged in investigating new approaches to diagnosing and treating diseases and conditions.

Doctors with patients

The clinical trials are done in close collaboration with scientists and physicians from many areas of expertise. All trials are overseen by the Institutional Review Board (IRB) to ensure the highest ethical standards. 

The following lists the clinical trials that are currently recruiting participants:


Effect of Addition of Steroids on Duration of Analgesia

The purpose of the study is to investigate the differences in post-procedural pain scores and narcotic use among patients who receive a Superior Hypogastric Nerve Block (SHNB) with and without corticosteroid performed as part of the Uterine Artery Embolization (UAE) procedure.

ClinicalTrials.gov identifier: NCT04126824

Contact: 
Halah Mansour,  310-794-5380,  [email protected]
Aniket Joglekar, 310-948-8026  [email protected]

If interested, please check out the eligibility criteria.


Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

ClinicalTrials.gov identifier: NCT05045027

Principal Investigator: Benjamin M. Ellingson

Contact: 
Saima Chaabane,  310-794-8995,  [email protected]
Halah Mansour,  310-794-5380,  [email protected]

If interested, please check out the eligibility criteria.


Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.

ClinicalTrials.gov identifier: NCT04765150

Principal Investigator: Kyung H Sung, PhD

Contact: Victoria Rueda, 310-794-8334,  [email protected]   

If interested, please check out the eligibility criteria.


Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

ClinicalTrials.gov identifier: NCT04315571

Principal Investigator: Edward W Lee, MD, PhD

Contact:
Arineh Aghakhani, 310-267-1268,  [email protected]  
Saima Chaabane, PhD. 310-794-8995,  [email protected]   

If interested, please check out the eligibility criteria.


BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

ClinicalTrials.gov identifier: NCT05003843

Contact: Victoria Rueda, 310-562-9694,  [email protected]
Contact: Aniket Joglekar, 310-948-8026,  aj[email protected]

If interested, please check out the eligibility criteria.


Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE

Magnetic resonance imaging (MRI) is used to measure liver fat content and fatty tissues in the body, and magnetic resonance elastography (MRE) is used to measure liver stiffness. The information from MRI and MRE are used to understand risk factors and diagnose liver diseases, such as fatty liver disease and liver fibrosis. However, current MRI and MRE scans need to be performed during a breath-hold, which may be challenging or impossible in children and infants. The goal of this research project is to develop and evaluate new free-breathing MRI and MRE technology to improve the comfort and diagnostic accuracy for children and infants.

ClinicalTrials.gov identifier: NCT04591106

Principal Investigator: Holden Wu, PhD

Contact: Holden Wu, PhD, 310-267-6843,  [email protected]
Contact: Kara Calkins, MD, 310-825-9330,  [email protected]

If interested, please check out the eligibility criteria.


Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (BVMN6203)

This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases.

The focus of this specific study is on Hemorrhagic Telangiectasia (HHT).

HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in the brain, nose, lungs, stomach, bowels and liver. Brain AVMs (BAVMs) in HHT are difficult to study because they are rare, affecting approximately 10% of people with HHT. While other types of BAVMs have been studied in depth, studies in the HHT population have been very small. Here, we propose the first large-scale collaboration by joining with 12 HHT Centers of Excellence in North America to perform a large study of risk factors for bleeding from BAVMs, called intracranial hemorrhage (ICH) in HHT patients.

The current standard of clinical practice across North America, is to screen all HHT patients for BAVMs with magnetic resonance imaging (MRI). If BAVMs are detected, patients are referred to a multidisciplinary neurovascular team for consideration for treatment. Treatment decisions are made on a case by case basis, balancing risks of complications from the BAVM with risks of therapy, but are limited by the few studies available in HHT. We hope that the knowledge we obtain about the risk factors for intracranial bleeding in these patients from this larger study will help us to improve the care of HHT patients.

We plan to study risk factors for rupture of BAVMs, including primarily genetics and imaging characteristics of the BAVMs. Knowledge about risk factors will help in the care and management of HHT patients. This will be achieved through the collection of health information to construct a HHT database, blood sampling and banking (through the National Institute of Neurological Disorders and Stroke [NINDS]), and through genetic analysis at the University of California San Francisco.

ClinicalTrials.gov identifier: NCT01158807

Principal Investigator: Justin McWilliams, MD

Contact: Victoria Rueda, MPH, 310-794-0376 ,  [email protected]  

If interested, please check out the eligibility criteria.


Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer

Tulsa pro diagram

A prospective, multi-center, single-arm study, planned in 110 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

ClinicalTrials.gov identifier: NCT02766543

Principal Investigator: Steve S. Raman, MD, FSAR, FSIR

Contact: Aniket Joglekar, (310) 948-8026,  [email protected]  

If interested, please check out the eligibility criteria.


Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

The standard clinical cardiovascular MRI practice for children with CHD frequently involves the use of gadolinium-based contrast agents (GBCA) to enhance tissue contrast. Most GBCAs are small molecules that quickly cross the capillary wall and access the interstitial space, a process which diminishes the signal contrast between blood vessels and surrounding tissue. Therefore, these types of GBCA are most useful for first-pass MR angiography, wherein the images are acquired quickly during the initial 15-30 seconds post-injection when the GBCA concentration is much higher in the arteries than in the interstitial space. For young children with complex CHD, the stringent requirements for high spatial resolution, and the need for cardiac gating and good blood-myocardium contrast in order to provide detailed evaluation of intracardiac structures are not compatible with conventional GBCA-based first-pass MR angiography. Even with Ablavar® (gadofosveset trisodium), an FDA approved GBCA with longer intravascular half-life than other GBCAs, cardiac-gated Ablavar®-enhanced MRI may be insufficient for young children with CHD based on our institutional experience and on data from the literature; there remains diminished blood-tissue contrast during the high-resolution cardiac-gated MRI. Furthermore, there have been safety concerns regarding gadolinium deposition in brain tissues after repeated GBCA exposure as well as concerns of nephrogenic systemic fibrosis (NSF) associated with GBCA injection in young children < 2 years old who may have immature renal function. The long-term health consequences of these effects in the pediatric population are unclear. For the above reasons, we seek to study the diagnostic imaging effectiveness of Feraheme (Feraheme®), an FDA-approved drug for parenteral iron supplementation, as an MRI contrast agent in children with CHD. Although Feraheme® has been approved for the treatment of iron deficiency anemia secondary to renal disease, Feraheme® has been used as an off-label MRI contrast agent at select medical centers.

ClinicalTrials.gov Identifier: NCT02752191

Contact: Maryann Burns, RT, 310-267-8745

Principal Investigator: Paul Finn, MD

If interested, please check out the eligibility criteria and contact Maryann Burns for more information.